CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-385

Oh and I should emphasise that this valuation between 50c and $1 is only based on the current financials that we already have. These are still only the early days though, there are many years of high growth ahead of EYE in my view. MIGS is a rapidly growing market, and EYE has what is arguably the best device. The strong and rapid adoption is pretty clear proof of that. Over the longer term, I’m looking for a price well over $10. That would only be a bit over a $2 billion market capitalisation, which I think is quite a realistic target. That is the beauty of investing in smaller stocks, whilst the volatility and frustration tends to be higher than it is for blue chips, the potential rewards certainly make up for that! It’s quite rare as well to find a stock valued this low that is already making substantial revenues and growing fast.